Metcure Therapeutics LLC

Atlanta, GA

UEI
CGKMNL6SUY65
CAGE
6XAH8
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Asian-Pacific American Owned
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
2693 Glenrose Hill, Atlanta, GA 30341, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Small-molecule therapy for metastatic castration-resistant prostate cancer - metastatic, castration-resistant… R42CA217491 National Cancer Institute (NIH) $4,878,167
Small-molecule therapy for metastatic prostate cancer R41CA217491 National Cancer Institute (NIH) $224,999
Novel small-molecule targeted therapy for prostate cancer R41CA206725 National Cancer Institute (NIH) $224,999
A dietary supplement as adjunct therapy in castration-resistant prostate cancer R41CA186498 National Institutes of Health $160,989

Quick answers

Is Metcure Therapeutics LLC registered in SAM.gov?

Yes. Metcure Therapeutics LLC's SAM.gov registration is active through April 8, 2027.

What is Metcure Therapeutics LLC's most recent federal award?

Metcure Therapeutics LLC's most recent federal grant award is Small-molecule therapy for metastatic castration-resistant prostate cancer - metastatic, castration-resistant… (R42CA217491), from National Cancer Institute (NIH), on August 1, 2017.

On GovTribe

See Metcure Therapeutics LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login